NEW YORK, N.Y.--(BUSINESS WIRE)--HepaLife Technologies, Inc. (OTCBB:HPLF) (FWB:HL1) (“HepaLife”), an advanced biomedical products company focused on the development and manufacturing of proprietary drug delivery and liver health technologies, today announced a 510(k) submission to the FDA by its AquaMed Technologies, Inc. (“AquaMed”) subsidiary seeking pre-market clearance for its silver based antimicrobial wound dressing.
